Combined therapy of prednisone and mTOR inhibitor sirolimus for treating retroperitoneal fibrosis.

Our combined therapy resulted in significant fibrosis remission and an overall regression of the immune system towards healthy states, while achieving good tolerance. We concluded that this new therapy had the potential to replace the steroid monotherapy for treating RPF.